210 related articles for article (PubMed ID: 38036980)
21. [Epidemiological survey of neonatal respiratory distress syndrome in part of northwest regions in China].
Network of Northwest Neonatal Professional Collaboration Group
Zhonghua Er Ke Za Zhi; 2015 May; 53(5):341-7. PubMed ID: 26080663
[TBL] [Abstract][Full Text] [Related]
22. Synthetic surfactant for respiratory distress syndrome in preterm infants.
Soll RF
Cochrane Database Syst Rev; 2000; 1998(2):CD001149. PubMed ID: 10796417
[TBL] [Abstract][Full Text] [Related]
23. Non-invasive high-frequency oscillatory ventilation versus nasal continuous positive airway pressure in preterm infants with respiratory distress syndrome: Study protocol for a multi-center prospective randomized controlled trial.
Zhu XW; Shi Y; Shi LP; Liu L; Xue J; Ramanathan R;
Trials; 2018 Jun; 19(1):319. PubMed ID: 29898763
[TBL] [Abstract][Full Text] [Related]
24. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome.
Soll RF; Blanco F
Cochrane Database Syst Rev; 2001; (2):CD000144. PubMed ID: 11405951
[TBL] [Abstract][Full Text] [Related]
25. Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome.
Soll R; Ozek E
Cochrane Database Syst Rev; 2009 Jan; (1):CD000141. PubMed ID: 19160177
[TBL] [Abstract][Full Text] [Related]
26. Animal derived surfactant extract for treatment of respiratory distress syndrome.
Seger N; Soll R
Cochrane Database Syst Rev; 2009 Apr; (2):CD007836. PubMed ID: 19370695
[TBL] [Abstract][Full Text] [Related]
27. Porcine versus bovine surfactant therapy for RDS in preterm neonates: pragmatic meta-analysis and review of physiopathological plausibility of the effects on extra-pulmonary outcomes.
Foligno S; De Luca D
Respir Res; 2020 Jan; 21(1):8. PubMed ID: 31910825
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants.
Soll RF
Cochrane Database Syst Rev; 2000; 1997(2):CD000511. PubMed ID: 10796380
[TBL] [Abstract][Full Text] [Related]
29. Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome.
Ardell S; Pfister RH; Soll R
Cochrane Database Syst Rev; 2015 Aug; 8(8):CD000144. PubMed ID: 26301526
[TBL] [Abstract][Full Text] [Related]
30. Less invasive surfactant administration versus intubation-surfactant-extubation in the treatment of neonatal respiratory distress syndrome: a systematic review and meta-analyses.
Silveira RC; Panceri C; Munõz NP; Carvalho MB; Fraga AC; Procianoy RS
J Pediatr (Rio J); 2024; 100(1):8-24. PubMed ID: 37353207
[TBL] [Abstract][Full Text] [Related]
31. CPAP failure in the management of preterm neonates with respiratory distress syndrome where surfactant is scarce. A prospective observational study.
Abdallah Y; Mkony M; Noorani M; Moshiro R; Bakari M; Manji K
BMC Pediatr; 2023 May; 23(1):211. PubMed ID: 37138252
[TBL] [Abstract][Full Text] [Related]
32. Effects of less invasive surfactant administration versus intubation-surfactant-extubation on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome: a single-center, retrospective study from China.
Xu CC; Bao YY; Zhao JX; Cheng K; Sun L; Wu JY; Wu MY; Zhu JJ
BMC Pulm Med; 2022 Dec; 22(1):462. PubMed ID: 36471386
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants.
Soll RF
Cochrane Database Syst Rev; 2000; (2):CD001079. PubMed ID: 10796410
[TBL] [Abstract][Full Text] [Related]
34. Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome.
Abdel-Latif ME; Davis PG; Wheeler KI; De Paoli AG; Dargaville PA
Cochrane Database Syst Rev; 2021 May; 5(5):CD011672. PubMed ID: 33970483
[TBL] [Abstract][Full Text] [Related]
35. Surfactant for pulmonary hemorrhage in neonates.
Aziz A; Ohlsson A
Cochrane Database Syst Rev; 2008 Apr; (2):CD005254. PubMed ID: 18425914
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the effect of surfactant administration during nasal continuous positive airway pressure with that of nasal continuous positive airway pressure alone on complications of respiratory distress syndrome: a randomized controlled study.
Nakhshab M; Tajbakhsh M; Khani S; Farhadi R
Pediatr Neonatol; 2015 Apr; 56(2):88-94. PubMed ID: 25264154
[TBL] [Abstract][Full Text] [Related]
37. The impact of combined administration of surfactant and intratracheal budesonide compared to surfactant alone on bronchopulmonary dysplasia (BPD) and mortality rate in preterm infants with respiratory distress syndrome: a single-blind randomized clinical trial.
Marzban A; Mokhtari S; Tavakkolian P; Mansouri R; Jafari N; Maleki A
BMC Pediatr; 2024 Apr; 24(1):262. PubMed ID: 38643076
[TBL] [Abstract][Full Text] [Related]
38. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Vermont-Oxford Neonatal Network.
Pediatrics; 1996 Jan; 97(1):1-6. PubMed ID: 8545199
[TBL] [Abstract][Full Text] [Related]
39. The influence of the technique of surfactant administration (LISA vs INSURE) on the outcomes of respiratory distress syndrome treatment in preterm infants.
Kaniewska U; Gulczyńska E
Dev Period Med; 2019; 23(3):163-171. PubMed ID: 31654994
[TBL] [Abstract][Full Text] [Related]
40. A risk-benefit assessment of natural and synthetic exogenous surfactants in the management of neonatal respiratory distress syndrome.
Walti H; Monset-Couchard M
Drug Saf; 1998 May; 18(5):321-37. PubMed ID: 9589844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
